It is found out that angiogenesis can be inhibited by a substance which inhibits the binding of a parathyroid hormone−associated peptide to its receptor. Namely, antitumor agents and bone metastasis inhibitors based on the inhibition of angiogenesis which contain as the active ingredient a substance capable of inhibiting the binding of a parathyroid hormone−associated peptide to its receptor.
